Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome.
Fleseriu et al. • 2012 • J Clin Endocrinol Metab. 2012;97(6):2039-49.
© 2024 Corcept Therapeutics, Incorporated
About jeremiah@devisedesigns.com
This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 134 entries already.
Entries by jeremiah@devisedesigns.com
Slowing the progression of cognitive decline in Alzheimer’s disease using mifepristone.
Belanoff et al. • 2002 • J Mol Neurosci. 2002;19(1-2):201-6.
Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486).
Chu et al. • 2001 • J Clin Endocrinol Metab. 2001;86(8):3568-73.